A positive trend in overall survival was observed, favoring sacituzumab govitecan over chemotherapy, though data is still immature. New trial results reveal sacituzumab govitecan shows promise for HR+ ...
– With Two Positive Phase 3 Trials, Trodelvy Has Potential as the First and Only ADC to be a Backbone Standard of Care for All First-Line Metastatic TNBC Patients Regardless of PD-L1 Status – Gilead ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback